Therapy for obesity based on gastrointestinal hormones

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Therapy for obesity based on gastrointestinal hormones. / Bagger, Jonatan I; Christensen, Mikkel; Knop, Filip K; Vilsboll, Tina.

In: Review of Diabetic Studies, Vol. 8, No. 3, 2011, p. 339-47.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bagger, JI, Christensen, M, Knop, FK & Vilsboll, T 2011, 'Therapy for obesity based on gastrointestinal hormones', Review of Diabetic Studies, vol. 8, no. 3, pp. 339-47. https://doi.org/10.1900/RDS.2011.8.339

APA

Bagger, J. I., Christensen, M., Knop, F. K., & Vilsboll, T. (2011). Therapy for obesity based on gastrointestinal hormones. Review of Diabetic Studies, 8(3), 339-47. https://doi.org/10.1900/RDS.2011.8.339

Vancouver

Bagger JI, Christensen M, Knop FK, Vilsboll T. Therapy for obesity based on gastrointestinal hormones. Review of Diabetic Studies. 2011;8(3):339-47. https://doi.org/10.1900/RDS.2011.8.339

Author

Bagger, Jonatan I ; Christensen, Mikkel ; Knop, Filip K ; Vilsboll, Tina. / Therapy for obesity based on gastrointestinal hormones. In: Review of Diabetic Studies. 2011 ; Vol. 8, No. 3. pp. 339-47.

Bibtex

@article{4f34a5e542a04163a8b041c8c047f408,
title = "Therapy for obesity based on gastrointestinal hormones",
abstract = "It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.",
author = "Bagger, {Jonatan I} and Mikkel Christensen and Knop, {Filip K} and Tina Vilsboll",
year = "2011",
doi = "http://dx.doi.org/10.1900/RDS.2011.8.339",
language = "English",
volume = "8",
pages = "339--47",
journal = "The Review of Diabetic Studies",
issn = "1613-6071",
publisher = "Society for Biomedical Diabetes Research (S B D R)",
number = "3",

}

RIS

TY - JOUR

T1 - Therapy for obesity based on gastrointestinal hormones

AU - Bagger, Jonatan I

AU - Christensen, Mikkel

AU - Knop, Filip K

AU - Vilsboll, Tina

PY - 2011

Y1 - 2011

N2 - It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.

AB - It has long been known that peptide hormones from the gastrointestinal tract have significant impact on the regulation of nutrient metabolism. Among these hormones, incretins have been found to increase insulin secretion, and thus incretin-based therapies have emerged as new modalities for the treatment of type 2 diabetes. In contrast to other antidiabetic treatments, these agents have a positive outcome profile on body weight. Worldwide there are 500 million obese people, and 3 million are dying every year from obesity-related diseases. Recently, incretin-based therapy was proposed for the treatment of obesity. Currently two different incretin therapies are widely used in the treatment of type 2 diabetes: 1) the GLP-1 receptor agonists which cause significant and sustained weight loss in overweight patients, and 2) dipeptidyl peptidase 4 (DPP-4) inhibitors being weight neutral. These findings have led to a greater interest in the physiology of intestinal peptides with potential weight-reducing properties. This review discusses the effects of the incretin-based therapies in obesity, and provides an overview of intestinal peptides with promising effects as potential new treatments for obesity.

U2 - http://dx.doi.org/10.1900/RDS.2011.8.339

DO - http://dx.doi.org/10.1900/RDS.2011.8.339

M3 - Journal article

VL - 8

SP - 339

EP - 347

JO - The Review of Diabetic Studies

JF - The Review of Diabetic Studies

SN - 1613-6071

IS - 3

ER -

ID: 40219325